My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Astellas Pharma Inc (OP:ALPMF)

16.60 +1.70 (+11.41%)

Streaming Delayed Price Updated: 11:29 AM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Astellas Pharma Inc

< Previous 1 2 Next >

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power ↗

November 12, 2025

Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.

Via Benzinga

Why Is Taysha Gene Therapies Stock Falling Friday? ↗

October 17, 2025

Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.

Via Benzinga

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients ↗

August 12, 2025

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for cisplatin therapy.

Via Benzinga

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study ↗

July 10, 2025

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported.

Via Benzinga

Astellas' Menopause Drug Under FDA Review ↗

August 18, 2022

Via Benzinga

JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre ↗

March 18, 2025

JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered.

Via Benzinga

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo ↗

February 11, 2025

Pfizer and Astellas' Padcev-Keytruda combo showed durable survival benefits in urothelial cancer, with a higher response rate and no new safety concerns.

Via Benzinga

Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise ↗

January 03, 2025

Elevation Oncology's ADCs target CLDN18.2 and HER3, with EO-3021 showing promising Phase 1 results and a $6.6 billion TAM in gastric and pancreatic cancers.

Via Benzinga

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact ↗

December 31, 2024

Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results.

Via Benzinga

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch ↗

October 16, 2024

William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales...

Via Benzinga

Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data ↗

August 05, 2024

Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage...

Via Benzinga

Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval ↗

May 17, 2024

Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo.

Via Benzinga

Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study ↗

October 05, 2023

Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant...

Via Benzinga

Why Is Seagen Stock Trading Higher Today? ↗

September 22, 2023

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC:

Via Benzinga

What's Going On With Neurology Focused Taysha Gene Therapies Stock Today? ↗

September 20, 2023

Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected

Via Benzinga

Why Shares of Adaptive Biotechnologies Jumped This Week ↗

June 16, 2023

The company could see its first FDA-approved therapy as early as next year.

Via The Motley Fool

Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles ↗

June 08, 2023

Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) decided to license and advance a gene therapy from Kate Therapeutics for a debilitating muscle disorder known as

Via Benzinga

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?

June 01, 2023

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?

Via News Direct

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition? ↗

May 30, 2023

The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio

Via Benzinga

Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories ↗

May 15, 2023

Bloomberg

Via Benzinga

Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback ↗

May 15, 2023

The FDA on Friday approved Japanese drugmaker Astellas Pharma Inc’s (OTC: ALPMY) (OTC: ALPMF) Veozah (fezolinetant) for hot flashes

Via Benzinga

Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58% ↗

May 01, 2023

Astellas Pharma Inc (OTC: ALPMY) and Pfizer Inc (NYSE: PFE) announced

Via Benzinga

Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration' ↗

May 01, 2023

Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of

Via Benzinga

FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer ↗

April 04, 2023

Via Benzinga

AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners ↗

March 28, 2023

Via Benzinga

Japanese Government Urges China To Release Astellas Pharma's Employee ↗

March 27, 2023

The Japanese government is reportedly seeking the release of an employee of Japanese pharma company Astellas Pharma Inc (OTC: ALPMF), detained by Chinese authorities. The reasons why the person was...

Via Benzinga

Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug ↗

March 17, 2023

Via Benzinga

Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts ↗

January 31, 2023

Via Benzinga

Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering ↗

January 24, 2023

Via Benzinga

Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs ↗

October 25, 2022

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.